Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 19, 44100 Ferrara, Italy.
Neuropharmacology. 2013 Sep;72:126-38. doi: 10.1016/j.neuropharm.2013.04.046. Epub 2013 May 3.
A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous dopamine to the motor actions of nociceptin/orphanin FQ (N/OFQ) receptor (NOP receptor) ligands. Motor activity was evaluated by a battery of behavioural tests in mice. The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice. Low doses of N/OFQ and NOP receptor antagonists promoted movement whereas higher doses inhibited it. Motor facilitation was selectively prevented by raclopride while motor inhibition was prevented by amisulpride. Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor l-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it. To dissect out the contribution of pre- and postsynaptic D2 receptors, mice lacking the D2 receptor (D2R(-/-)) or its long isoform (D2L(-/-)) were used. Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and pramipexole) was lost in D2R(-/-) but preserved in D2L(-/-) mice. N/OFQ-induced hypolocomotion was observed in both genotypes. We demonstrate that motor actions of NOP receptor ligands rely on the modulation of endogenous dopamine. Motor facilitation induced by NOP receptor antagonists as well as low dose N/OFQ is mediated through D2L postsynaptic receptors whereas motor inhibition observed with higher doses of N/OFQ occurs by direct inhibition of mesencephalic DA neurons. Motor inhibition seen with high doses of NOP receptor antagonists appears to be mediated through the D2 presynaptic autoreceptors. These data confirm that endogenous N/OFQ is a powerful modulator of dopamine transmission in vivo and that the effects of NOP receptor antagonists on motor function reflect the blockade of this endogenous N/OFQ tone.
采用药理学和遗传学相结合的方法,研究内源性多巴胺对孤啡肽/孤啡肽原(N/OFQ)受体(NOP 受体)配体运动作用的贡献。通过一系列行为测试评估小鼠的运动活动。使用 D1/D5(SCH23390)、D2/D3(raclopride、amisulpride)和 D3(S33084)受体拮抗剂以及 D2 受体敲除小鼠,评估 N/OFQ 和 NOP 受体拮抗剂的各种 DA 受体亚型在运动效应中的作用。低剂量的 N/OFQ 和 NOP 受体拮抗剂促进运动,而高剂量的则抑制运动。Raclopride 选择性地阻止运动兴奋,而 amisulpride 阻止运动抑制。Amisulpride 还减弱了 D2/D3 受体激动剂普拉克索和多巴胺前体 l-3,4-二羟基苯丙氨酸诱导的运动迟缓,而 raclopride(和 S33084)则加重了这种作用。为了剖析突触前和突触后 D2 受体的作用,使用缺乏 D2 受体(D2R(-/-))或其长亚型(D2L(-/-))的小鼠。N/OFQ 和 NOP 受体拮抗剂诱导的运动兴奋在 D2R(-/-)和 D2L(-/-)小鼠中丧失,而 NOP 受体拮抗剂(和普拉克索)诱导的运动抑制在 D2R(-/-)小鼠中丧失,但在 D2L(-/-)小鼠中保留。两种基因型均观察到 N/OFQ 诱导的运动迟缓。我们证明,NOP 受体配体的运动作用依赖于内源性多巴胺的调节。NOP 受体拮抗剂诱导的运动兴奋以及低剂量 N/OFQ 是通过 D2L 突触后受体介导的,而高剂量 N/OFQ 引起的运动抑制是通过对中脑 DA 神经元的直接抑制引起的。高剂量 NOP 受体拮抗剂引起的运动抑制似乎是通过 D2 突触前自身受体介导的。这些数据证实内源性 N/OFQ 是体内多巴胺传递的强大调节剂,并且 NOP 受体拮抗剂对运动功能的影响反映了这种内源性 N/OFQ 张力的阻断。